Doctors stop dementia medications when they no longer help slow cognitive decline, when side effects become more harmful than the medications’ benefits, or when a person’s health and care goals shift toward comfort rather than aggressive treatment. There isn’t a single universal trigger—the decision depends on the individual’s stage of dementia, overall health, how their body tolerates the medication, and what matters most to them and their family. For example, a patient on donepezil (Aricept) who shows no improvement in memory after two years and develops nausea and weight loss might stop the medication to improve daily quality of life, even though the drug itself is still prescribed for mild-to-moderate dementia.
The timing of medication discontinuation is deeply personal. Some people benefit from staying on medications longer, while others experience side effects so troubling that stopping becomes the right choice earlier. There’s no failure in stopping a medication—it’s a rational medical decision that reflects changing health circumstances, not a giving up on care.
Table of Contents
- WHEN MEDICATIONS LOSE EFFECTIVENESS
- SIDE EFFECTS AND SAFETY CONCERNS
- ADVANCED DEMENTIA AND MEDICATION FUTILITY
- COORDINATING WITH OVERALL HEALTH GOALS
- MEDICATION-SPECIFIC DISCONTINUATION PATTERNS
- MONITORING FOR CHANGES AFTER STOPPING
- CONVERSATIONS WITH FAMILY AND CARE PARTNERS
WHEN MEDICATIONS LOSE EFFECTIVENESS
dementia medications like cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine work by slowing cognitive decline in early-to-moderate stages. They don’t stop or reverse dementia, and they don’t work indefinitely. Once someone reaches advanced or late-stage dementia—when they can no longer recognize family members, communicate verbally, or perform daily activities—these medications typically stop working because there’s too little remaining brain function for the drug to support. A doctor might continue monitoring for benefits for 6 to 12 months after starting, then recommend discontinuation if there’s no measurable improvement in cognition, function, or behavior.
In some cases, a person plateaus on medication rather than continuing to improve. For instance, someone might stabilize at a certain level of memory and function for years, which is actually a success of the medication preventing further decline. But if cognitive decline accelerates despite the medication, or if no improvement appears within a reasonable timeframe, continuing the drug offers less justification, especially if side effects are present. Doctors also consider whether the medication is addressing the actual problems the person is experiencing. If someone with dementia is primarily struggling with depression, anxiety, or behavioral symptoms, a cognition-slowing drug may not help those issues, and stopping it to focus on treating mood or behavior might improve overall quality of life.
SIDE EFFECTS AND SAFETY CONCERNS
Dementia medications can cause nausea, diarrhea, muscle weakness, dizziness, and slowed heart rate—side effects that are particularly dangerous for older adults who already face high fall risk. A person on donepezil who becomes lightheaded and falls repeatedly has a serious injury risk; in that case, stopping the medication and allowing heart rate and blood pressure to stabilize is often the safer choice than continuing a cognitive medication while dealing with fall-related fractures. These medications also interact with other drugs commonly used in older age, like certain blood pressure medicines or pain relievers, and stopping one medication may allow better management of others. GI issues are especially common and particularly concerning for people with dementia who may not communicate discomfort clearly.
Severe nausea or diarrhea can lead to malnutrition, weight loss, and dehydration—conditions that actually harm cognition more than the original dementia does. Some patients also develop behavioral or psychiatric side effects: increased anxiety, vivid nightmares, or emotional outbursts, sometimes misattributed to the dementia itself rather than the medication. The longer someone is on a dementia medication, the more their body adapts, and side effects sometimes worsen rather than improve. A medication that worked well at diagnosis might become poorly tolerated five years later, making discontinuation necessary even if the drug could theoretically still help cognition.
ADVANCED DEMENTIA AND MEDICATION FUTILITY
In advanced dementia, the brain damage is so extensive that slowing cognitive decline becomes essentially impossible—there’s already very little cognitive function left to preserve. Someone in the late stage of dementia cannot perform activities of daily living, often cannot recognize loved ones, may not communicate with words, and experiences difficulty swallowing. Research shows that continuing cholinesterase inhibitors or memantine in this stage offers no measurable benefit and exposes the person to medication risks without gain.
At this point, comfort-focused care—managing pain, ensuring good nutrition and hydration, keeping the person clean and comfortable—becomes far more important than cognitive medications. A practical example: a family might have kept their parent on donepezil throughout moderate dementia because it seemed to help, but when their parent stops recognizing them, stops eating voluntarily, and requires full physical assistance with everything, the doctor would typically recommend stopping the medication to reduce pill burden and focus on comfort. The goal shifts from “try to slow decline” to “keep them comfortable and dignity-focused.” Some medications are discontinued more quickly than others. Memantine (Namenda), used for moderate-to-severe dementia, has less research showing long-term benefit and may be stopped sooner than cholinesterase inhibitors, especially if side effects appear or swallowing becomes difficult (a major risk for any oral medication in advanced dementia).
COORDINATING WITH OVERALL HEALTH GOALS
When a person with dementia develops a serious health condition—advanced heart disease, cancer, end-stage kidney disease—their medical team often shifts into a goals-of-care discussion. If the person’s primary goal becomes managing pain and spending time with family rather than extending life, cognitive medications might be stopped to simplify medication regimens and reduce potential drug interactions or side effects that could interfere with comfort care. A person on four cardiac medications and two diabetes drugs has less capacity to tolerate additional side effects from dementia medications.
This decision involves the person with dementia (if they still have decision-making capacity), their family, their primary care doctor, and often a geriatrician or palliative care specialist. The conversation centers on: What matters most to this person now? What is the realistic goal of medication therapy? Is the medication preventing suffering or contributing to it? Stopping a dementia medication is not a minor adjustment—it requires clear communication about what to expect and whether the person or family will be monitoring for changes in behavior or cognition. Some families worry that stopping medication means “giving up.” Doctors should explicitly explain that shifting from cognitive medications to comfort-focused care is not abandonment but a change in priorities that often improves the person’s day-to-day experience.
MEDICATION-SPECIFIC DISCONTINUATION PATTERNS
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are typically continued as long as they’re tolerated and showing benefit, but many are stopped in advanced dementia or if side effects like severe nausea, bradycardia (slow heart rate), or syncope (fainting) appear. If a doctor recommends stopping, the medication should usually be tapered gradually over a few weeks rather than stopped abruptly, because abrupt discontinuation can cause temporary behavioral or cognitive changes and may trigger other side effects. Memantine has a different safety profile—it’s generally well-tolerated—but long-term benefit data is thinner, so doctors more often see it stopped at the advanced dementia stage.
N-methyl-D-aspartate (NMDA) receptor antagonists like memantine are especially concerning if someone develops urinary retention, confusion, or hallucinations, and these side effects prompt earlier discontinuation. Antipsychotics prescribed for behavioral symptoms in dementia (like risperidone or aripiprazole) carry a black-box warning for increased mortality in older adults with dementia, so these are often discontinued if the behaviors they were meant to manage can be addressed through other means—environmental changes, activity schedules, addressing pain or constipation underlying the behavior—or if the person’s behavior has improved over time. Unlike cognition-slowing medications, antipsychotics are meant to be used at the lowest effective dose for the shortest necessary duration.
MONITORING FOR CHANGES AFTER STOPPING
When a dementia medication is discontinued, families often ask whether the person will “get worse.” The honest answer is that some people show no noticeable change, while others may have a temporary increase in behavioral symptoms or a subtle acceleration of cognitive decline that was being partially masked by the medication. The decline that appears after stopping a medication was already happening—the medication was just slowing it slightly—but the family may perceive it as a sudden worsening caused by stopping treatment. Doctors should set this expectation in advance.
Family members should be prepared to observe and report any significant behavioral changes, new confusion, agitation, or mood shifts in the weeks after discontinuation. Most changes that occur stabilize within a few weeks. If a person’s condition deteriorates markedly, the doctor should investigate whether something else is wrong—a urinary tract infection, pain, medication interaction, or new medical problem—rather than immediately restarting the dementia medication, though restarting is always an option if benefits reappear and side effects were the only reason for stopping.
CONVERSATIONS WITH FAMILY AND CARE PARTNERS
The decision to stop dementia medications should never be made in isolation. A doctor should present the reasoning clearly—why continuing is no longer helping, why side effects matter, what the person’s expected trajectory is with or without the medication—and invite family input. Family members sometimes push back, fearing that stopping medication means the person will decline faster, but research and clinical experience show that in late-stage dementia or when side effects are severe, continuing the medication doesn’t provide cognitive benefit and often worsens quality of life.
This conversation is ideally held proactively, not as a last-minute decision when the person is in crisis. Ideally, it happens during an earlier dementia stage when the person with dementia may still participate, or shortly after diagnosis when family is gathering information. Some families benefit from speaking with a palliative care doctor or geriatrician separately from the primary care doctor, to hear a second perspective and understand that stopping medication is a standard, evidence-based decision, not a failure of treatment. The goal is alignment: everyone understanding that the medication is no longer serving the person’s wellbeing and that the focus is shifting to comfort, dignity, and maintaining connection.
- —
